Fisher Buys Lancaster Laboratories

Article

Fisher Buys Lancaster Laboratories

Fisher Scientific, Inc. (Hampton, NH) has acquired Lancaster Laboratories, Inc. (Lancaster, PA) for $125 million. The deal closed during the first week of August. Lancaster had been owned by private equity firm Goldner Hawn Johnson and Morrison (Minneapolis, MN), which acquired Lancaster five years ago from Thermo Electron Corporation. Industry insiders say the bidding for Lancaster was highly competitive, and the purchase price is said to represent a substantial multiple of sales and earnings.

The deal brings together two companies with market-leading positions in pharmaceutical services: Fisher Clinical Services in clinical packaging, and Lancaster Labs in analytical chemistry and microbiology. The acquisition gives Fisher Clinical substantial capabilities in analytical services, something it has wanted for some time. It also gives parent company Fisher Scientific a bigger piece of the R&D spend of major pharmaceutical companies, where it is already a big provider of laboratory supplies and consumables and clinical packaging.

The Lancaster Labs deal is Fisher Clinical’s second big acquisition of the summer. In May, Fisher acquired McKesson BioServices, in Rockville, MD, and renamed it Fisher BioServices. BioServices provides biological sample storage and clinical supplies distribution services, and has major contracts with several of the National Institutes of Health.

–Jim Miller

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content